Page 121 - 80 guidelines for the treatment of malaria_opt

ANNEX 3. Pharmacology of antimalarial medicines

69. Mansor SM et al. Effect of Plasmodium falciparum malaria infection on the plasma
concentration of alpha 1-acid glycoprotein and the binding of quinine in Malawian children.
British Journal of Clinical Pharmacology, 1991, 32:317–321.
70. Phillips RE et al. Quinine pharmacokinetics and toxicity in pregnant and lactating women
with falciparum malaria. British Journal of Clinical Pharmacology, 1986, 21:677–683.
71. Hall AP et al. Human plasma and urine quinine levels following tablets, capsules, and
intravenous infusion. Clinical Pharmacology and Therapeutics, 1973, 14:580–585.
72. Pukrittayakamee S et al. A study of the factors affecting the metabolic clearance of quinine
in malaria. European Journal of Clinical Pharmacology, 1997, 52:487–493.
73. Newton PN et al. Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum A3
malaria with acute renal failure. Transactions of the Royal Society of Tropical Medicine and
Hygiene, 1999, 93:69–72.
74. Bruce-Chwatt LJ. Quinine and the mystery of blackwater fever. Acta Leidensia, 1987,
55:181–196.
75. White NJ, Looareesuwan S, Warrell DA. Quinine and quinidine: a comparison of EKG
effects during the treatment of malaria. Journal of Cardiovascular Pharmacology, 1983,
5:173–175.
76. Boland ME, Roper SM, Henry JA. Complications of quinine poisoning. Lancet, 1985,
1:384–385.
77. Pukrittayakamee S, et al. Adverse effect of rifampicin on quinine efficacy in uncomplicated
falciparum malaria. Antimicrobial Agents and Chemotherapy, 2003, 47:1509-1513.
78. Newton PN et al. The Pharmacokinetics of oral doxycycline during combination treatment of
severe falciparum malaria. Antimicrobial Agents and Chemotherapy, 2005, 49:1622–1625.
79. Atuah KN, Hughes D, Pirmohamed M. Clinical pharmacology: special safety considerations
in drug development and pharmacovigilance. Drug Safety, 2004, 27:535–554.
80. Ginsberg G et al. Pediatric pharmacokinetic data: implications for environmental risk
assessment for children. Pediatrics, 2004, 113(4 Suppl.):973–983.
81. Shankar AH. Nutritional modulation of malaria morbidity and mortality. Journal of
Infectious Diseases, 2000, 182(Suppl. 1):S37–S53.
82. de Onis M et al. The worldwide magnitude of protein-energy malnutrition: an overview from
the WHO Global Database on Child Growth. Bulletin of the World Health Organization,
1993, 71:703–712.
83. Wolday D et al. Sensitivity of Plasmodium falciparum in vivo to chloroquine and
pyrimethamine-sulfadoxine in Rwandan patients in a refugee camp in Zaire. Transactions
of the Royal Society of Tropical Medicine and Hygiene, 1995, 89:654–656.
84. Wellcome Trust Working Party. Classification of infantile malnutrition. Lancet, 1970,
2:302–303.
85. Wharton BA, McChesney EW. Chloroquine metabolism in kwashiorkor. Journal of Tropical
Pediatrics, 1970, 16:130–132.
86. Walker O et al. Single dose disposition of chloroquine in kwashiorkor and normal children –
evidence for decreased absorption in kwashiorkor. British Journal of Clinical Pharmacology,
1987, 23:467–472.

107